Xeltis today announces that it has successfully completed the first feasibility clinical trial on Endogenous Tissue Restoration (ETR). In this study, five children born with only one heart ventricle instead of two healthy, functioning ventricles that pump blood throughout the body, were implanted with Xeltis’ vascular graft and were followed up for 12 months. “The results of this study are remarkable. At 12 months follow-up, all clinical parameters are positive and all indicators show that patients have successfully grown their own blood vessels”, Prof. Leo Bockeria, renowned cardiac surgeon at the Bakoulev Center for Cardiovascular Surgery of the Russian Academy of Medical Sciences in Moscow, states. Laurent Grandidier, CEO at Xeltis, adds “The successful completion of our first clinical trial marks the advent of a paradigm shift in cardiovascular treatments. We believe it will be possible one day to replace most commonly used implantable cardiovascular devices by Xeltis’ technology.”
